Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).

导出 OA

翻译打印收藏纠错

作者： Ohsang,Kwon ^[1] ; Maryanne M,Senna ^[2] ; Rodney,Sinclair ^[3] ; Taisuke,Ito ^[4] ; Yves,Dutronc ^[5] ; Chen-Yen,Lin ^[5] ; Guanglei,Yu ^[5] ; Chiara,Chiasserini ^[5] ; Jill,McCollam ^[5] ; Wen-Shuo,Wu ^[5] ; Brett,King ^[6]

作者单位： Department of Dermatology, Seoul National University College of Medicine, 103 Daehak-ro, Ihwa-dong, Jongno-gu, Seoul, 03080, Republic of Korea. oskwon@snu.ac.kr. ^[1] Division of Dermatology, Lahey Hospital and Medical Center, and Harvard Medical School, Boston, MA, USA. ^[2] Sinclair Dermatology, Melbourne, VIC, Australia. ^[3] Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. ^[4] Eli Lilly and Company, Indianapolis, IN, USA. ^[5] Yale School of Medicine, New Haven, CT, USA. ^[6]

主题词成年人(Adult);人类(Humans);斑秃(Alopecia Areata)

DOI 10.1007/s40257-023-00764-w

PMID 36855020

发布时间 2023-05-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交